international
Ozempic-like drugs may improve kidney disease outcomes: study
Key takeaways
- Semaglutide is a GLP-1 agonist sold under the brand names of Ozempic and Wegovy.
- New research shows people with type 2 diabetes and chronic kidney disease who took semaglutide (commonly sold as Ozempic) once a week had improved kidney outcomes, even if they have heart disease or heart failure.
- This builds on previous research which found the drug had "consistent benefits" preventing heart attacks, strokes, and death due to cardiovascular causes in those with chronic kidney disease.
Why this matters: an international story with cross-border implications worth tracking.
Semaglutide is a GLP-1 agonist sold under the brand names of Ozempic and Wegovy. (Reuters: Hollie Adams)
New research shows people with type 2 diabetes and chronic kidney disease who took semaglutide (commonly sold as Ozempic) once a week had improved kidney outcomes, even if they have heart disease or heart failure.
This builds on previous research which found the drug had "consistent benefits" preventing heart attacks, strokes, and death due to cardiovascular causes in those with chronic kidney disease.
Article preview — originally published by ABC Australia. Full story at the source.
Read full story on ABC Australia →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from ABC Australia alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop